These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32072887)

  • 1. Monoclonal Antibodies: A Prospective and Retrospective View.
    Sivaccumar J; Sandomenico A; Vitagliano L; Ruvo M
    Curr Med Chem; 2021; 28(3):435-471. PubMed ID: 32072887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs.
    Aires da Silva F; Corte-Real S; Goncalves J
    BioDrugs; 2008; 22(5):301-14. PubMed ID: 18778112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis.
    Janowitz T
    Protein Eng Des Sel; 2011 Jan; 24(1-2):105-11. PubMed ID: 21037277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development of next generation of antibody-based therapeutics.
    Li J; Zhu Z
    Acta Pharmacol Sin; 2010 Sep; 31(9):1198-207. PubMed ID: 20694021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.
    Kholodenko RV; Kalinovsky DV; Doronin II; Ponomarev ED; Kholodenko IV
    Curr Med Chem; 2019; 26(3):396-426. PubMed ID: 28820071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.
    Flego M; Ascione A; Cianfriglia M; Vella S
    BMC Med; 2013 Jan; 11():4. PubMed ID: 23289632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of therapeutic antibodies for the treatment of diseases.
    Lu RM; Hwang YC; Liu IJ; Lee CC; Tsai HZ; Li HJ; Wu HC
    J Biomed Sci; 2020 Jan; 27(1):1. PubMed ID: 31894001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The coming of age of engineered multivalent antibodies.
    Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
    Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
    Teillaud JL
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody treatments for rheumatoid arthritis.
    Bossaller L; Rothe A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1257-72. PubMed ID: 23789825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted biopharmaceuticals for cancer treatment.
    Zhou L; Xu N; Sun Y; Liu XM
    Cancer Lett; 2014 Oct; 352(2):145-51. PubMed ID: 25016064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
    Sewell F; Chapman K; Couch J; Dempster M; Heidel S; Loberg L; Maier C; Maclachlan TK; Todd M; van der Laan JW
    MAbs; 2017 Jul; 9(5):742-755. PubMed ID: 28475417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for the development of therapeutic monoclonal antibodies.
    Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
    Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic monoclonal antibodies in ophthalmology.
    Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
    Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metrics for antibody therapeutics development.
    Reichert JM
    MAbs; 2010; 2(6):695-700. PubMed ID: 20930555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.